Inhibition of PI3K/mTOR leads to adaptive resistance in matrix-attached cancer cells. - Wikidata - wikimedia - TriplyDB

Inhibition of PI3K/mTOR leads to adaptive resistance in matrix-attached cancer cells.

Inhibition of PI3K/mTOR leads to adaptive resistance in matrix-attached cancer cells.

http://www.wikidata.org/entity/Q35816378

about

Synthetic lethal interaction of combined BCL-XL and MEK inhibition promotes tumor regressions in KRAS mutant cancer models Cap-Independent Translational Control of Carcinogenesis Tumor-Derived Cell Lines as Molecular Models of Cancer Pharmacogenomics IGF-1 Receptor and Adhesion Signaling: An Important Axis in Determining Cancer Cell Phenotype and Therapy Resistance What a tangled web we weave: emerging resistance mechanisms to inhibition of the phosphoinositide 3-kinase pathway Pushing tumor cells towards a malignant phenotype: stimuli from the microenvironment, intercellular communications and alternative roads CDK 4/6 inhibitors sensitize PIK3CA mutant breast cancer to PI3K inhibitors.The phosphoinositide 3-kinase pathway and therapy resistance in cancer Systematic identification of combinatorial drivers and targets in cancer cell lines Identification of ovarian cancer metastatic miRNAs Quantification of dynamic morphological drug responses in 3D organotypic cell cultures by automated image analysis Integration of molecular profiling and chemical imaging to elucidate fibroblast-microenvironment impact on cancer cell phenotype and endocrine resistance in breast cancer Activation of the PI3K/mTOR pathway is involved in cystic proliferation of cholangiocytes of the PCK rat Disrupting the networks of cancer Synergistic apoptosis in head and neck squamous cell carcinoma cells by co-inhibition of insulin-like growth factor-1 receptor signaling and compensatory signaling pathways.Enhancing the evaluation of PI3K inhibitors through 3D melanoma models.Starved epithelial cells uptake extracellular matrix for survival.Development of transplantable human chordoma xenograft for preclinical assessment of novel therapeutic strategies.ROS signaling under metabolic stress: cross-talk between AMPK and AKT pathway.Biomarker-guided sequential targeted therapies to overcome therapy resistance in rapidly evolving highly aggressive mammary tumors.Unification of de novo and acquired ibrutinib resistance in mantle cell lymphoma.Preclinical therapeutic efficacy of a novel blood-brain barrier-penetrant dual PI3K/mTOR inhibitor with preferential response in PI3K/PTEN mutant glioma.ERBB receptors: from oncogene discovery to basic science to mechanism-based cancer therapeutics.ZEB1 sensitizes lung adenocarcinoma to metastasis suppression by PI3K antagonism.Rapid induction of apoptosis by PI3K inhibitors is dependent upon their transient inhibition of RAS-ERK signaling.Niche-localized tumor cells are protected from HER2-targeted therapy via upregulation of an anti-apoptotic program in vivo.FoxO transcription factors promote AKT Ser473 phosphorylation and renal tumor growth in response to pharmacologic inhibition of the PI3K-AKT pathway Fibroblast heterogeneity in the cancer wound.Mammalian Target of Rapamycin Inhibitors Resistance Mechanisms in Clear Cell Renal Cell Carcinoma.Mirk/dyrk1B kinase is upregulated following inhibition of mTOR.Force engages vinculin and promotes tumor progression by enhancing PI3K activation of phosphatidylinositol (3,4,5)-triphosphate.Genetically engineered mouse models of PI3K signaling in breast cancer.Mirk kinase inhibition blocks the in vivo growth of pancreatic cancer cells.Suppression of feedback loops mediated by PI3K/mTOR induces multiple overactivation of compensatory pathways: an unintended consequence leading to drug resistance.Diacylglycerol kinase α promotes 3D cancer cell growth and limits drug sensitivity through functional interaction with Src.Copy number gain of hsa-miR-569 at 3q26.2 leads to loss of TP53INP1 and aggressiveness of epithelial cancers.PKD1 mediates negative feedback of PI3K/Akt activation in response to G protein-coupled receptors.Prolyl-4-hydroxylase α subunit 2 promotes breast cancer progression and metastasis by regulating collagen deposition.Three-dimensional organotypic culture: experimental models of mammalian biology and disease.Translational horizons in the tumor microenvironment: harnessing breakthroughs and targeting cures.

P2860

Q24306326-5D295C9F-6548-49A2-BDA9-B2B3DAD022AF Q26744030-EE6C14FB-2C6A-4732-83F5-48049EDBB783 Q26801410-FBE3DABB-DB83-41B5-81D0-81D8DA3A92E7 Q26802042-90D5EC9F-7068-474A-8373-C501FF8B3230 Q26825780-0166D260-B6EF-478F-8F23-485252EE589D Q26830075-39F7B230-3513-409B-BE8E-6A7B1164DB3C Q27853037-2CA93761-C998-4666-AC4C-9BCE069EA014 Q28082811-C81A7E88-88B8-4441-B3BF-D9DD41B7E88D Q28486051-87481098-1ED8-416A-A1FF-535899304193 Q28487932-B82D4B5D-79FF-4832-A955-7604DB60057F Q28538607-7997BEC9-1824-49FF-9D6D-C65E83E23A86 Q28538685-9E169889-102E-4B19-8C48-66299F324458 Q28573157-3D76ED9D-7148-4326-BCAF-CE0C6055F0DC Q28656016-31068F88-D403-459D-B835-7C1CEB42494B Q30458494-450FEC28-3296-480A-8B96-4E13524A5CA2 Q30746265-C19C7E13-2B69-4968-9C68-E54657D5777A Q30834870-7350D61A-D97E-4B45-B215-7E6E6F6C6799 Q33275064-0265BE38-9B1D-491D-AB99-68E6615DF4B0 Q33560337-B1E5220C-6D62-47C7-9EB5-EBA5A15CD64C Q33571352-214F9150-85AF-4EF9-843B-00C071A36A78 Q33587128-5A907A20-2392-43CF-8C1A-09286654F6AF Q33591658-1720DC99-1E03-47CF-A72C-801F9335D6DF Q33601653-BBF208BA-8182-4CF3-8292-B0373D3EF197 Q33685931-5F71E4C6-0C0E-4D7B-8017-C9804F0F454F Q33726847-6DBF80F2-3A90-457E-AFC8-73DB26EF8846 Q33767497-27B2470A-23D0-49DC-82D8-9D4804EE8DD9 Q33864477-C6D00002-20CD-4BAB-8EF2-CFF65811AEA3 Q33964324-0889BA86-1F35-4965-BBB2-CCE11E349AC2 Q34077263-66E19580-8B08-4B30-B496-9A6208A79A17 Q34096774-DCD0E0DF-2153-4D15-8A6B-815E62FBC196 Q34315046-C2271F34-D4BC-4931-A896-12AD21C1F6E2 Q34332175-C5C65EEB-05F6-4AB8-B9FB-A4F4C552E94A Q34405468-43B4C10C-35BA-4F3B-B0F6-A414386E2976 Q34466060-825BF44E-586E-4192-9D9D-39B23818A960 Q34654588-9420AE85-3489-4BEF-A17E-59F71C09CBA2 Q34664892-4519856D-BF12-4EA5-992B-5F44D40CAFE4 Q34988846-0D440470-C9F1-4E60-BABE-CA3B43B77AB2 Q35079475-B2B16366-9096-407C-9DDE-144BC86A95F0 Q35155660-81E80EF3-9B9A-499A-B111-8046C8652BF5 Q35219539-97DCCB55-D48B-4C0F-B8F9-AE3C60B708BE

P2860

Inhibition of PI3K/mTOR leads to adaptive resistance in matrix-attached cancer cells.

http://www.wikidata.org/entity/Q35816378

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

2012年论文

@zh

2012年论文

@zh-cn

name

Inhibition of PI3K/mTOR leads to adaptive resistance in matrix-attached cancer cells.

@ast

Inhibition of PI3K/mTOR leads to adaptive resistance in matrix-attached cancer cells.

@en

type

label

Inhibition of PI3K/mTOR leads to adaptive resistance in matrix-attached cancer cells.

@ast

Inhibition of PI3K/mTOR leads to adaptive resistance in matrix-attached cancer cells.

@en

prefLabel

Inhibition of PI3K/mTOR leads to adaptive resistance in matrix-attached cancer cells.

@ast

Inhibition of PI3K/mTOR leads to adaptive resistance in matrix-attached cancer cells.

@en

P1433

Q35816378-1ECA45D4-D3A2-44A7-8B48-68B804F7520E

P1476

Q35816378-6B8299C9-54A6-4FB8-8F3F-0272588A7E93

P2093

Q35816378-2E3255AC-E5D2-45A7-AD81-1EDD1C4D71CE

Q35816378-34EA218E-AA67-4806-8484-3A8324A0EFF9

Q35816378-37755B72-0064-4A6F-A498-C76EEB5B023F

Q35816378-7B0CBE97-76A3-4EE3-99D4-15FE08777336

Q35816378-7C1472B6-07C3-4D4E-8B56-A4527C6AD93B

Q35816378-A3354E0B-7971-48DB-B7F1-BAA5F86392A4

Q35816378-B4226B84-31A5-4F7B-8007-593EC32E26AD

Q35816378-C06ACE58-FC0B-4B58-BD4F-F03466F6DC51

P2860

Q35816378-083666DF-0818-474B-8211-F6349F9AECF7

Q35816378-106FBBD5-E87F-4C44-804B-559425DE44B5

Q35816378-1A1E9C26-B57D-4963-8D5B-053501C383D4

Q35816378-2052327B-A192-4B44-815B-28E115183BED

Q35816378-2B8060EE-6498-4C9D-B3B2-A08A392F7115

Q35816378-2D4A60DB-1620-445E-A922-CAD26B1C934B

Q35816378-2D7E348A-D6D6-4965-BFD5-2AB4966F1F40

Q35816378-305EBFB6-1FB0-4812-9062-98BE2ACF4CB4

Q35816378-31E8B21F-87E8-4AFD-B65C-5D26EC8AA9D7

Q35816378-342A46B7-E83A-4DDC-A187-1A2849E07A4B

P304

Q35816378-BB09B255-112E-40E3-865E-1885B05812BB

P31

Q35816378-C2514DD0-5FCC-4E15-A936-C2BDCA1E37B8

P356

Q35816378-7846CB13-06AF-4C8E-B9AB-D5BBA44B45D3

P433

Q35816378-EAF18FD5-2957-4DAE-AB43-544048B09525

P478

Q35816378-4CA33960-6799-409D-83DA-F315A25EF758

P50

Q35816378-970C8749-2524-48DE-823A-4506B67846F8

P577

Q35816378-7913BDA5-536E-43F6-89A2-BBBAA236C71E

P5875

Q35816378-5640620F-030F-4AD4-8E8B-DF26D1D58A8C

P698

Q35816378-D863E5EA-26F3-4EC7-80D5-069D219C4E6B

P932

Q35816378-6B11977A-F09B-41C8-BC11-1A6076BF1019

P356

J.CCR.2011.12.024

P1433

P1476

Inhibition of PI3K/mTOR leads to adaptive resistance in matrix-attached cancer cells.

@en

P2093

Devin T Worster

http://www.w3.org/2001/XMLSchema#string

Fabiana C Morales

http://www.w3.org/2001/XMLSchema#string

Gordon B Mills

http://www.w3.org/2001/XMLSchema#string

Joan S Brugge

http://www.w3.org/2001/XMLSchema#string

Laura M Selfors

http://www.w3.org/2001/XMLSchema#string

Loling Song

http://www.w3.org/2001/XMLSchema#string

Marcin P Iwanicki

http://www.w3.org/2001/XMLSchema#string

Sizhen Gao

http://www.w3.org/2001/XMLSchema#string

P2860

Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2

Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor

Direct control of the Forkhead transcription factor AFX by protein kinase B

PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer

The PI3K pathway as drug target in human cancer

Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3

A transforming mutation in the pleckstrin homology domain of AKT1 in cancer

Discovery of (thienopyrimidin-2-yl)aminopyrimidines as potent, selective, and orally available pan-PI3-kinase and dual pan-PI3-kinase/mTOR inhibitors for the treatment of cancer

Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers.

PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer

P304

227-239

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.CCR.2011.12.024

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

21

http://www.w3.org/2001/XMLSchema#string

P50

P577

2012-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

221838191

http://www.w3.org/2001/XMLSchema#string

P698

22340595

http://www.w3.org/2001/XMLSchema#string

P932

3297962

http://www.w3.org/2001/XMLSchema#string